A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). (Q50956087)

5 July 2018

title

A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). (English)

1 reference

5 July 2018

1 reference

1 reference

Glen J Weiss

1

1 reference

5 July 2018

Jordan Waypa

2

1 reference

5 July 2018

Lisa Blaydorn

3

1 reference

5 July 2018

Jessica Coats

4

1 reference

5 July 2018

Kayla McGahey

5

1 reference

5 July 2018

Ashish Sangal

6

1 reference

5 July 2018

Jiaxin Niu

7

1 reference

5 July 2018

Cynthia A Lynch

8

1 reference

5 July 2018

John H Farley

9

1 reference

5 July 2018

Vivek Khemka

10

1 reference

5 July 2018

language of work or name

English

0 references

publication date

6 June 2017

1 reference

5 July 2018

British Journal of Cancer

published in

1 reference

5 July 2018

volume

117

1 reference

5 July 2018

issue

1

1 reference

5 July 2018

page(s)

33-40

1 reference

5 July 2018

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

copyright license

start time

1 June 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/bjc.2017.145

0 references

cites work

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5520208

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5520208

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5520208

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5520208

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5520208

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5520208

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5520208

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5520208

Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5520208

Immunological off-target effects of standard treatments in gastrointestinal cancers

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5520208

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5520208

Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5520208

Nivolumab plus ipilimumab in advanced melanoma

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5520208

Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue.

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5520208

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5520208

The secret ally: immunostimulation by anticancer drugs

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5520208

Immune parameters affecting the efficacy of chemotherapeutic regimens

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5520208

Dose escalation methods in phase I cancer clinical trials

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5520208

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

10 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5520208

10 July 2018

Identifiers

DOI

10.1038/BJC.2017.145

1 reference

5 July 2018

PMCID

5520208

1 reference

5 July 2018

PubMed ID

28588322

1 reference

5 July 2018